Latest Intelligence on Central Nervous System

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Antipsychotics: market growth to tail off

Published By Datamonitor
23 Mar 2001
ResearchWire
ResearchWire

Antipsychotics: new classes dominate early stage development

Published By Datamonitor
01 Feb 2002
ResearchWire
ResearchWire

Antipsychotics: new classes to make an impact

Published By Datamonitor
20 Mar 2001
ResearchWire
ResearchWire

Antipsychotics: pharmaceutical companies control late stage R&D

Published By Datamonitor
24 Jul 2001
ResearchWire
ResearchWire

Antipsychotics: sales up $2 billion by 2008

Published By Datamonitor
04 Jul 2003
ResearchWire
ResearchWire

Anxiety disorders: global sales set to slide

Published By Datamonitor
03 May 2006
CommentWire
CommentWire

Anxiety: a day to raise awareness - and drug revenues

Published By Datamonitor
19 Apr 2001
CommentWire
CommentWire

APA 2010: Alkermes prepares to enter potentially lucrative opioid dependence market

At this year's American Psychiatric Association meeting, US pharmaceutical company Alkermes presented promising new data for Vivitrol in the treatment of opioid dependence. The FDA is currently assessing the drug under a priority review, and approval in the burgeoning opioid dependence indication would be a major boon for Alkermes.

Published By Datamonitor
10 Jun 2010
Expert View
Expert View

APA 2010: limited data highlight unmet needs in bipolar disorder

Several leading drug makers presented new data in bipolar disorder at this year's meeting of the American Psychiatric Association. Despite Cephalon's Nuvigil showing promise as an adjunct, modest data for antipsychotics from Merck & Co and Pfizer served only to highlight the remaining unmet needs in the treatment of this disease.

Published By Datamonitor
08 Jun 2010
Expert View
Expert View

APA 2010: Merck and Dainippon take center stage to present new schizophrenia therapies

Schizophrenia played a prominent role at this year's American Psychiatric Association Annual Meeting due to the prevailing high level of unmet need. Merck & Co and Dainippon Sumitomo presented data for new drugs which Datamonitor believes represent important additions to the current treatment portfolio. Elsewhere, an interesting lecture predicted a future of personalized schizophrenia treatments.

Published By Datamonitor
08 Jun 2010

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.